Guardion Health Sciences (NASDAQ:GHSI) and Correvio Pharma (NASDAQ:CORV) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.
This table compares Guardion Health Sciences and Correvio Pharma’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Guardion Health Sciences||N/A||N/A||N/A|
Institutional & Insider Ownership
46.2% of Correvio Pharma shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
This is a summary of current recommendations for Guardion Health Sciences and Correvio Pharma, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Guardion Health Sciences||0||0||0||0||N/A|
Correvio Pharma has a consensus target price of $8.17, suggesting a potential upside of 247.52%. Given Correvio Pharma’s higher possible upside, analysts plainly believe Correvio Pharma is more favorable than Guardion Health Sciences.
Earnings and Valuation
This table compares Guardion Health Sciences and Correvio Pharma’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Guardion Health Sciences||$940,000.00||32.78||-$7.77 million||N/A||N/A|
|Correvio Pharma||$28.67 million||3.27||-$16.58 million||($0.89)||-2.64|
Guardion Health Sciences has higher earnings, but lower revenue than Correvio Pharma.
Guardion Health Sciences beats Correvio Pharma on 5 of the 9 factors compared between the two stocks.
About Guardion Health Sciences
Guardion Health Sciences, Inc., a specialty health sciences company, develops, formulates, and distributes condition-specific medical foods in the United States and internationally. It operates in two segments, Medical Foods and Vision Testing Diagnostics. The Medical Foods segment offers Lumega-Z, a medical food that replenishes and restores the macular protective pigment; MapcatSF, a medical device that measures the macular pigment optical density; and GlaucoCetin, a vision-specific medical food to support and protect the mitochondrial function of optic nerve cells, as well as improve blood flow in the ophthalmic artery in patients with glaucoma. The Vision Testing Diagnostics segment develops, manufactures, and sells equipment and supplies for standardized vision testing for use by eye doctors in clinical trials, real-world vision evaluation, and industrial vision testing. Its products include VectorVision CSV-1000, an instrument for contrast sensitivity testing; and ESV-3000 ETDRS, a device for early treatment diabetic retinopathy study in visual acuity testing. The company distributes its products through direct sales force, as well as through its guardionhealth.com Website. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in San Diego, California.
About Correvio Pharma
Correvio Pharma Corp. operates as a pharmaceutical company, which engages in the provision of development and commercialization of medical products. It operates through the Europe and Rest of the World geographical segments. The firm focuses on cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease. It offers the Brinavess and Aggrastat products to customers such as physicians, patients, and healthcare systems. The company was founded in 1986 and is headquartered in Vancouver, Canada.
Receive News & Ratings for Guardion Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardion Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.